2020 AABB Annual Meeting On-Demand

Oct 3, 2020 ‐ Oct 3, 2020



Access to the 2020 AABB Annual Meeting On-Demand sessions expires on December 31, 2022. Each session includes the on-demand recording and a downloadable MP3 audio file. Presentation handouts are not available/included.

Planning Committee Disclosures


Sessions

AM20-22: COVID-19 Convalescent Plasma - Optimizing Collection Strategies and State of RCTs

Oct 4, 2020 11:15am ‐ Oct 4, 2020 12:15pm
Expiration Date: Dec 31, 2022

Credits: None available.

During this session, we will review the PassItOn study from Vanderbilt University and a prophylaxis clinical trial from Johns Hopkins to better understand the methodology, design, and status of these trials. The session will also feature discussions of how best to optimize collection of COVID-19 convalescent plasma in terms of (1) workflow and (2) maximizing the safe collection of high antibody titer units.

Learning Objectives:
  • Employ changes and optimize to their donor management workflow
  • Establish criteria for frequent plasma collections that recognizes the need to preserve donor safety
  • Determine whether their hospital, staff, or patients can be enrolled in one of the ongoing RCTs for CCP
Speaker(s):
  • Dr. Evan M. Bloch, MD, Associate Professor; Associate Director, Transfusion Medicine, Johns Hopkins University School of Medicine
  • Dr. Claudia S. Cohn, MD, PhD, Chief Medical Officer, Associate Professor of Laboratory Medicine and Pathology, Director, Blood Bank Laboratory, Associate Director, Clinical Laboratories, University of Minnesota
  • Dr. Bruce S. Sachais, MD, PhD, New York Blood Center
Moderator(s): Disclosures
  • Evan Bloch, MD : Honoraria: Grifols, Terumo
  • Claudia Cohn, MD, PhD : Honoraria: Octapharma, Terumo
  • Eduardo Nunes, MPP, CAE : Nothing to disclose
  • Bruce Sachais, MD, PhD : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-23: Does Assessing Vital Signs Contribute to Blood Donation Safety?

Oct 4, 2020 11:15am ‐ Oct 4, 2020 12:15pm
Expiration Date: Dec 31, 2022

Credits: None available.

Blood services depend upon healthy blood donors to provide a safe and adequate supply of blood products. With a shrinking donor base, many blood collection agencies are challenging blood donor eligibility regulations that lack scientific basis. Several studies, in and outside of the United States (US), document the relatively poor correlation of donor vital signs outside of normal range and subsequent adverse donor reactions to collection. This session will explore and compare the requirements for vital signs to determine donor eligibility in the US, and the experience of other countries on donor safety after changing vital signs requirements for determination of donor eligibility. In this session, the Donor Health and Safety Committee and the Donor Hemovigilance Working Group will present the following: 1) an overview of donor vital signs regulations in the Code of Federal Regulations that govern donor eligibility in the US and the evidence supporting consideration of change; 2) a summary of the changes made by Canadian Blood Services/ Hema-Quebec related to blood donor vital signs requirements and their experience following implementation; 3) an overview of changes related to requirement of pre-donation vital signs in the Australia and the impact on donor safety; and 4) the position of the Food and Drug Administration on blood pressure and pulse as blood donor eligibility criteria.

Learning Objectives:
  • Discuss evidence supporting and refuting the utility of assessing vital signs for safety of blood collection.
  • Compare the current regulations and recommendations regarding donor eligibility requirements in the United States, Canada, Australia and other countries.
  • Summarize the evidence related to the impact of blood pressure and pulse on syncopal reactions and cardiac events.
Speaker(s):
  • Dr. Mindy Goldman, MD, Medical Director, Donor & Clinical Services, Canadian Blood Services
  • Prof. David O. Irving, Australian Red Cross Blood Service
  • Dr. Jed B. Gorlin, MD, MBA, Medical Director and Vice President, Quality and Regulatory Affairs, Co-Director, Transfusion Medicine, Associate Clinical Professor, Laboratory Medicine and Pediatrics, Innovative Blood Resources
Disclosures
  • Mindy Goldman, MD : Nothing to disclose
  • Jed Gorlin, MD, MBA : Consultant: Ativa Biomedical
  • David Irving : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-24: Innovative Alternatives to Platelet Transfusion

Oct 4, 2020 11:15am ‐ Oct 4, 2020 12:15pm
Expiration Date: Dec 31, 2022

Credits: None available.

Presented in collaboration with Be The Match BioTherapies®

The increased understanding of the biological events underlying the generation of platelets from megakaryocytes led to the development of novel strategies that might eventually supplement or replace donor-derived platelet transfusions. Ex vivo manufacturing of platelets from primary hematopoietic stem cells or from induced pluripotent stem cells has been pursued and near-clinical doses of platelets have been achieved by utilizing highly optimized ex vivo cultures and/or state-of-the-art bioreactors. In addition, megakaryocyte-biased cellular products that have the ability to naturally release platelets in the patient’s own body after infusion have been proposed to mitigate repeated platelet transfusions. Clinical implementation of these approaches has the potential to overcome the limitations associated with donor-dependent platelet transfusions such as risk of bacterial contamination, alloimmunization and refractoriness. Furthermore, these novel strategies have the potential to mitigate the increasing demand for donor platelet transfusions which is compounded by dependency on volunteer donors, short storage time and lifespan after infusion as well as shortages in supply due to inclement weather and holidays. This session will review three different approaches to the standard platelet transfusions. Each presenter will highlight the biological basis, process and description of product development as well as manufacturing and regulatory strategies to advance these cellular products to the clinic. Attendees will require a general understanding of human thrombocytopoiesis, i.e. platelet production in vivo and ex vivo, and development of cellular products as therapeutics along with the knowledge of the clinical indications for platelet transfusions and associated risks.

Learning Objectives:
  • Recognize the process of megakaryocytes and platelets generation from hematopoietic stem cells.
  • Distinguish between the new megakaryocyte or platelet-based cellular products and the traditional platelet transfusion products.
  • Appreciate that despite the advances and potential clinical impact of the new cellular products, manufacturing, safety and regulatory features require critical considerations prior to administering such products to patients.
Speaker(s): Disclosures
  • Camelia Iancu-Rubin, PhD : Research/Grant Support: Tacitus Therapeutics; Consultant: Tacitus Therapeutics
  • Avital Mendelson, PhD : Nothing to disclose
  • Joseph Italiano, PhD : Consultant: Platelet Bio; Stockholder/Board of Directors: PlateletBio
Standard: $25.00
Members: $20.00

AM20-25: A Step Above the Basics of HLA for Apheresis/Transfusion Practitioners

Oct 4, 2020 2:30pm ‐ Oct 4, 2020 3:30pm
Expiration Date: Dec 31, 2022

Credits: None available.

HLA can be a difficult and cumbersome topic to understand, yet it is important for the transfusion/apheresis practitioner to be able to interpret the significance of HLA testing results and apply it to clinical decision making. To address this, last year we began with the “Basics of HLA for Apheresis Practitioners”, which reviewed the fundamentals of HLA nomenclature, testing methodologies, reporting, and common areas of confusion (“Level 1.0”). This year’s session will pick up from where last year’s session left off and progress the audience to higher level scenarios (“Level 2.0”). Don’t worry if you did not attend last year’s session – this is meant to be friendly to all audience members and key concepts will be (briefly!) recapped where appropriate. This session will use case-based learning to highlight essential take-home points as well as delving into some of the more nuanced scenarios. We will demonstrate how to access and use some of the online tools, databases, and resources commonly used by HLA experts. The goal is to empower the audience in their understanding of HLA, build their confidence in communicating with other teams on HLA-relevant topics (e.g. transplant service, HLA lab, donor center), and improve their independence in interpreting HLA testing reports and applying that understanding to clinical decision making in transfusion, transplantation, and apheresis.

Learning Objectives:
  • Interpret and differentiate between the various components of an HLA testing report.
  • Explain various factors that can negatively or positively interfere with test results.
  • Utilize online tools, databases, websites, and other online resources commonly utilized by HLA experts.
  • Recommend follow-up actions (e.g. additional testing, performing an apheresis procedure) and/or question their clinical usefulness as appropriate to the circumstance.
Speaker(s):
  • Dr. Patricia Kopko, MD, Professor of Pathology, Director of Transfusion Medicine, Associate Director, Immunogenetics and Transplantation Laboratory, Associate Director, Pathology Residency Training Program, University of California San Diego
  • Harold Sullivan, MD, Emory University School of Medicine
  • Dr. Deanna C. Fang, MD, UC San Diego School of Medicine
Disclosures
  • Deanna Fang, MD : Nothing to disclose
  • Patricia Kopko, MD : Nothing to disclose
  • Harold Sullivan, MD : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-26: Practical Tales of Red Cell Genotyping: Through the Eyes of the Molecular Biologist, Serologist, and Physician

Oct 4, 2020 2:30pm ‐ Oct 4, 2020 3:30pm
Expiration Date: Dec 31, 2022

Credits: None available.

This interactive session provides a practical approach to understand and evaluate blood group genotyping from the perspective of a genotyper, an immunohematology serologist and a transfusion medicine clinician. Common red cell genomics terminology, concepts, and applications will be discussed to improve the participant’s ability to interpret red cell genotyping reports. The session will equip practitioners with knowledge to understand how to utilize genotyping as a powerful tool to assist in the provision of transfusion support to a patient. Important test limitations of serology and genotyping will be explained. Case studies from red cell serology, to DNA testing, to the clinical relevance will be presented to expand and enhance the knowledge of the serologist and physician to improve patient care.

Learning Objectives:
  • Explain the basic concepts and nomenclature in blood group genetics
  • Describe methods utilized in blood group genotyping and identify differences of blood group antigens based on blood group genotyping
  • Apply blood group genotyping to clinical situations
Speaker(s): Disclosures
  • Meghan Delaney, DO, MPH : Grant/research Support: Terumo BCT
  • Michael Gannett, MLS(ASCP)SBB : Nothing to disclose
  • Sunitha Vege : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-27: Oral Abstract Session -- Data Driven Clinical Practice

Oct 4, 2020 2:30pm ‐ Oct 4, 2020 3:30pm
Expiration Date: Dec 31, 2022

Credits: None available.

Oral abstract session on Data Driven Clinical Practice

Learning Objectives:
  • Describe current trends in transfusion-related adverse reactions in the United States.
  • Explain how machine learning can be used to predict intraoperative blood utilization.
  • Examine the frequency of therapeutic plasmapheresis for thrombotic thrombocytopenic purpura (TTP) during pregnancy.
  • Summarize the how a novel clot retraction assay can guide clinical platelet transfusion practices.
Speaker(s): Disclosures
  • Prajeeda Nair, PhD : Nothing to disclose
  • Ian Kracalik, MPH, PhD : Nothing to disclose
  • Ryan Metalf : Nothing to disclose
  • Sirisha Kundrapu, MD, MS : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-28: Implementing the FDA Guidance for Industry of Platelets: Bacterial Risk Control Strategies from a Blood Center and Transfusion Service Perspective

Oct 4, 2020 3:45pm ‐ Oct 4, 2020 4:45pm
Expiration Date: Dec 31, 2022

Credits: None available.

The Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion was issued September 2019 with an 18-month implementation time frame.

This session will address the implementation steps taken at a large metropolitan hospital, and a major organization that includes five blood centers.

It will include the questions asked, decisions made, challenges that were overcome, and the regulatory steps taken to implement. It will address the different options to comply with the FDA Guidance, hospital customers concern and final outcomes.

Learning Objectives:
  • Illustrate the steps taken at a large metropolitan hospital to know what the hospital must do to adhere to the guidance and know what they are receiving from their multiple blood suppliers. Discuss how they will know if the product has a 5-day expiration or requires secondary testing. Discuss how they will decide to go with Pathogen Reduced platelets and if they will be readily available.
  • Discuss how to implement the guidance at a multiple facility blood center system. A system with multiple collection systems.
  • Predict how to determine what your customers preferences are while planning what products to produce.
  • Discuss all regulatory steps taken to implement the guidance including questions asked of the FDA.
Speaker(s): Disclosures
  • Christine Driscoll : Nothing to disclose
  • Sarai Paradiso, BS MT(ASCP) : Nothing to disclose
  • Leana Serrano-Rahman, MPH, (MT)ASCP, (CQA)ASQ : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-29: Test Your Blood Bank Knowledge 2020

Oct 4, 2020 3:45pm ‐ Oct 4, 2020 4:45pm
Expiration Date: Dec 31, 2022

Credits: None available.

This is the time to show off your blood bank knowledge by participating in a challenging blood bank game show! Using a game show format, multiple-choice questions will be presented to the audience in categories corresponding to the ASCP SBB and BB Exam Content Outline. The scores will be tallied by audience response technology allowing participants to be part of the ACTION! The questions range from the basic to esoteric blood bank knowledge, inviting all levels of AABB attendees to get involved in this fun and challenging session. The technology tracks the scores of the participants leading to the “Final Challenge Question," which determines the participants with the highest scores for Test Your Blood Bank Knowledge 2020.

Learning Objectives:
  • Relate basic to advanced knowledge in blood banking/transfusion medicine in an interactive question and answer format.
  • Select topics based on the ASCP BB/SBB Exam Content Outline which will challenge participants to recall technical, scientific and management information.
  • Incorporate entertainment while allowing participants to assess and expand their blood bank knowledge.
Speaker(s): Disclosures
  • Karen Byrne : Nothing to disclose
  • Wyenona Hicks, MS, MT(ASCP)SBB : Nothing to disclose
  • LeeAnn Walker, MEd, MT(ASCP)SBB : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-30: Supporting Genetic Therapies for Sickle Cell Disease (ASH/AABB Joint Session)

Oct 4, 2020 3:45pm ‐ Oct 4, 2020 4:45pm
Expiration Date: Dec 31, 2022

Credits: None available.

Presented in collaboration with Be The Match BioTherapies®

Cellular therapies for treating SCD are expanding at a rapid pace, with multiple approaches in trials and under development. Most of the therapeutic approaches use stem cell transplantation with genetically modified HSC, to generate red cells resistant to sickling. Emerging therapies include gene addition of beta globin, Bcl11a modification as well as other gene and base editing techniques being performed at both academic and industry research laboratories. While there are promising early results from clinical trials using gene therapy, more work is required to understand how to optimize stem cell collection, transplantation and engraftment.

To develop novel cell therapies, a concerted effort to link clinicians, patients, researchers and industry to move the field forward. In our session, we will review the current landscape of SCD therapies and to discuss how the initiative functions to identify and support initiatives. We will discuss the therapeutic clinical trials and review the clinical indicators used to assess successful outcomes. Lastly, we will discuss preparative transfusion therapies to optimize mobilization and collection of stem cells and to improve outcome of stem cell transplantation. The latter therapies heavily rely on the expertise of transfusion medicine specialists. Together, this presentation seeks to demonstrate the multimodal approaches of cell therapy for sickle cell disease.

The target audience is wide and includes: 

• Blood bank technicians and managers to understand transfusion needs
• Apheresis clinicians who perform red cell exchange and stem cell collection
• Hematologists and Stem Cell Transplant clinicians interested in trials and clinical therapeutic endpoints
• Patients and their advocates to understand the multi-modal nature of the novel cell therapies
• Scientific program managers that allocate resources and balance efforts within an initiative

Learning Objectives:
  • Appreciate the wide range of participants to effect novel cell therapies for sickle cell disease
  • Update of clinical trials and assess outcomes of clinical trials for sickle cell disease
  • Review transfusion therapies and stem cell collection for cellular therapy of sickle cell disease
Speaker(s): Disclosures
  • John Manis, MD : Consultant: SQZ Biotech, Sanofi
  • Mark Walters, MD : Consultant: Veevos, Editas Medical; Medical Director: AllCells Inc.
  • Lis Welniak : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-31: Plenary Oral Abstract Session

Oct 4, 2020 6:00pm ‐ Oct 4, 2020 7:00pm
Expiration Date: Dec 31, 2022

Credits: None available.

Oral abstract session on Plenary Oral Abstracts

Learning Objectives:
  • Discuss the results of a prospective, randomized controlled trial of a novel plasma collection normogram to safely increase plasmapheresis yield.
  • Describe the identification of an F-actin binding protein in platelet production and its potential as a target for increasing ex vivo platelet manufacturing.
  • Discuss the design of a high throughput DNA mass spectroscopy assay for identification of uncommon and rare blood group antigens.
Speaker(s): Disclosures
  • Jane Hartmann : <p><br></p>
  • Seema Bhatlekar, MBA : <p><br></p>
  • Aaron Gottschalk : <p><br></p>
Standard: $25.00
Members: $20.00